Skip to main content
Contact Us
Subscribe
E-Edition
81°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silexion Therapeutics Corp - Ordinary Shares
(NQ:
SLXN
)
0.9400
-0.0500 (-5.05%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Apr 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silexion Therapeutics Corp - Ordinary Shares
< Previous
1
2
3
Next >
TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%
January 29, 2025
“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 29, 2025
Via
Benzinga
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
January 29, 2025
U.S. stock futures were mixed ahead of the crucial earnings from key U.S. technology companies and the Fed's expected pause on rate cuts.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
January 29, 2025
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
January 28, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
January 28, 2025
Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.
Via
Benzinga
Check out the stocks that are attracting the most attention and driving market activity.
January 28, 2025
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today.
Via
Chartmill
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
January 28, 2025
Via
Benzinga
These stocks are moving in today's session
January 28, 2025
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
January 28, 2025
Via
Benzinga
The market is filled with gapping stocks in Tuesday's session.
January 28, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
January 28, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
January 16, 2025
Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials planned for 2026.
Via
Benzinga
PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
January 16, 2025
From
PESG
Via
Business Wire
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures
January 16, 2025
Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.
Via
Stocktwits
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
January 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 16, 2025
Via
Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
January 16, 2025
Via
Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
December 19, 2024
Via
Benzinga
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
December 17, 2024
From
PESG Research
Via
Business Wire
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
December 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 06, 2024
Via
Benzinga
Agilent, Bath & Body Works And 3 Stocks To Watch Heading Into Monday
November 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 20, 2024
Via
Benzinga
What's Going On With Silexion Therapeutics Shares Wednesday?
November 20, 2024
Silexion Therapeutics shares are moving higher on Wednesday after the company reported that Guangzhou Sino-Israel bio-industry investment fund holds a decent stake in the company.
Via
Benzinga
US Stocks Mostly Lower; Target Posts Downbeat Earnings
November 20, 2024
Via
Benzinga
Ilan Hadar, CEO of Silexion Therapeutics Corp. (NASDAQ: SLXN), to Present at NobleCon20
November 14, 2024
Via
Investor Brand Network
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications.
Via
News Direct
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.